Benzinga | Jan 18, 2022 09:28AM EST

B of A Securities Maintains Underperform on Integra Lifesciences, Raises Price Target to $65

B of A Securities analyst Craig Bijou maintains Integra Lifesciences (NASDAQ:IART) with a Underperform and raises the price target from $55 to $65.